Oral and Injectable Dual Formulation Strategy Gains Momentum

Onconic Therapeutics’ P-CAB new drug “Zastaprazan” (marketed domestically as “Zaqubo”) is accelerating its push into the Chinese gastroesophageal reflux disease (GERD) treatment market, estimated to be worth around 6 trillion won. With its Chinese partner Livzon Pharmaceutical currently undergoing regulatory review for product approval, the company has set in motion a dual formulation strategy—combining both oral and injectable forms of Zastaprazan—by advancing follow-up Phase 3 clinical trials for the injectable after already conducting H. pylori eradication therapy trials.

Onconic Therapeutics Research Institute Exterior. Onconic Therapeutics

Onconic Therapeutics Research Institute Exterior. Onconic Therapeutics

View original image

On September 23, Onconic Therapeutics announced that its Chinese technology licensing partner Livzon Pharmaceutical has begun dosing the first patient this month, officially launching the Phase 3 clinical trial for the injectable formulation of Zastaprazan in China. This trial is designed to assess the efficacy and safety of Zastaprazan injection in patients with bleeding peptic ulcers. In line with the contract terms, Onconic Therapeutics has issued an additional claim to Livzon for a development milestone payment worth 1 million dollars.


The oral formulation of Zastaprazan for the treatment of erosive GERD was submitted for product approval to the National Medical Products Administration (NMPA) of China in August of last year and is currently under review. In May of this year, a Phase 3 clinical trial for H. pylori eradication therapy was also initiated. Livzon Pharmaceutical, in its annual report, outlined a “dual-dosage form” strategy, aiming to expand both indications and dosage forms concurrently for Zastaprazan's oral and injectable formulations.


According to data citing market research firm IQVIA, the global GERD treatment market is valued at approximately 40 trillion won, with the Chinese market estimated at 4 trillion to 6 trillion won. Livzon is a leading local pharmaceutical company in the gastrointestinal therapeutics sector, generating annual sales of more than 600 billion won in this area and holding a strong sales and distribution network within China.


The collaboration between the two companies is translating into tangible revenue as development progresses. In 2023, Onconic Therapeutics entered into a Greater China technology transfer agreement with Livzon worth a total of 127.5 million dollars, receiving 15 million dollars (about 20 billion won at that time) as an upfront payment. The company has continued to achieve additional milestone payments with each development stage, securing a further 5 million dollars (about 7 billion won at that time) following the completion of Phase 3 clinical trials in China and submission for NMPA product approval in August of last year. As key developments, such as the most recent injectable Phase 3 trial, are consecutively resulting in milestone income, the achievements in technology transfer—stemming from the expansion of indications and dosage forms—are becoming more visible.



An official from Onconic Therapeutics stated, “Since the large-scale technology transfer in 2023, major clinical development achievements have continued one after another, so we expect Zastaprazan’s commercial value in China to be fully realized following product approval.” The official added, “We also plan to further strengthen our partnership with Livzon.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing